Skip to main content
Journal cover image

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Publication ,  Journal Article
Kim, BJ; Ying, G-S; Huang, J; Levy, NE; Maguire, MG; CATT Research Group
Published in: Am J Ophthalmol
July 2014

PURPOSE: To evaluate transient, large visual acuity (VA) decreases, termed sporadic vision loss, during anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD). DESIGN: Cohort within a randomized clinical trial. METHODS: setting: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). study population: Total of 1185 CATT patients. main outcome measures: Incidence of sporadic vision loss and odds ratio (OR) for association with patient and ocular factors. Sporadic vision loss was a decline of ≥15 letters from the previous visit, followed by a return at the next visit to no more than 5 letters worse than the visit before the VA loss. RESULTS: There were 143 sporadic vision loss events in 122 of 1185 patients (10.3%). Mean VA at 2 years for those with and without sporadic vision loss was 58.5 (∼20/63) and 68.4 (∼20/40) letters, respectively (P < .001). Among patients treated pro re nata, no injection was given for 27.6% (27/98) of sporadic vision loss events. Multivariate analysis demonstrated that baseline predictors for sporadic vision loss included worse baseline VA (OR 2.92, 95% confidence interval [CI]:1.65-5.17 for ≤20/200 compared with ≥20/40), scar (OR 2.21, 95% CI:1.22-4.01), intraretinal foveal fluid on optical coherence tomography (OR 1.80, 95% CI:1.11-2.91), and medical history of anxiety (OR 1.90, 95% CI:1.12-3.24) and syncope (OR 2.75, 95% CI:1.45-5.22). Refraction decreased the likelihood of sporadic vision loss (OR 0.62, 95%CI: 0.42-0.91). CONCLUSIONS: Approximately 10% of CATT patients had sporadic vision loss. Baseline predictors included AMD-related factors and factors independent of AMD. These data are relevant for clinicians in practice and those involved in clinical trials.

Duke Scholars

Published In

Am J Ophthalmol

DOI

EISSN

1879-1891

Publication Date

July 2014

Volume

158

Issue

1

Start / End Page

128 / 135.e10

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vision Tests
  • Vision Disorders
  • Vascular Endothelial Growth Factor A
  • Tomography, Optical Coherence
  • Ranibizumab
  • Prospective Studies
  • Ophthalmology & Optometry
  • Odds Ratio
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kim, B. J., Ying, G.-S., Huang, J., Levy, N. E., Maguire, M. G., & CATT Research Group. (2014). Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol, 158(1), 128-135.e10. https://doi.org/10.1016/j.ajo.2014.04.004
Kim, Benjamin J., Gui-Shuang Ying, Jiayan Huang, Nicole E. Levy, Maureen G. Maguire, and CATT Research Group. “Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Am J Ophthalmol 158, no. 1 (July 2014): 128-135.e10. https://doi.org/10.1016/j.ajo.2014.04.004.
Kim BJ, Ying G-S, Huang J, Levy NE, Maguire MG, CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10.
Kim, Benjamin J., et al. “Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Am J Ophthalmol, vol. 158, no. 1, July 2014, pp. 128-135.e10. Pubmed, doi:10.1016/j.ajo.2014.04.004.
Kim BJ, Ying G-S, Huang J, Levy NE, Maguire MG, CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10.
Journal cover image

Published In

Am J Ophthalmol

DOI

EISSN

1879-1891

Publication Date

July 2014

Volume

158

Issue

1

Start / End Page

128 / 135.e10

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vision Tests
  • Vision Disorders
  • Vascular Endothelial Growth Factor A
  • Tomography, Optical Coherence
  • Ranibizumab
  • Prospective Studies
  • Ophthalmology & Optometry
  • Odds Ratio